Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis

NCT00662649 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00662649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00662649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
June 30, 2011
Enrollment
920 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis